The discovery of antitumor immunotherapies targeting tumor-induced angiogenesis (e.g., VEGF-A, VEGFR-2) have been proposed as a universal therapeutic strategy to improve the clinical outcome of patients with several solid tumor types, as breast cancer [18,26]. The gene discussed is VEGFA; the disease is breast carcinoma.